Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Details
Publication Year 2024-01-25,Volume 143,Issue #4,Page 336-341
Journal Title
Blood
Publication Type
Research article
Abstract
Assessment of measurable residual disease (MRD) by quantitative reverse transcription polymerase chain reaction is strongly prognostic in patients with NPM1-mutated acute myeloid leukemia (AML) treated with intensive chemotherapy; however, there are no data regarding its utility in venetoclax-based nonintensive therapy, despite high efficacy in this genotype. We analyzed the prognostic impact of NPM1 MRD in an international real-world cohort of 76 previously untreated patients with NPM1-mutated AML who achieved complete remission (CR)/CR with incomplete hematological recovery following treatment with venetoclax and hypomethylating agents (HMAs) or low-dose cytarabine (LDAC). A total of 44 patients (58%) achieved bone marrow (BM) MRD negativity, and a further 14 (18%) achieved a reduction of ≥4 log10 from baseline as their best response, with no difference between HMAs and LDAC. The cumulative rates of BM MRD negativity by the end of cycles 2, 4, and 6 were 25%, 47%, and 50%, respectively. Patients achieving BM MRD negativity by the end of cycle 4 had 2-year overall of 84% compared with 46% if MRD was positive. On multivariable analyses, MRD negativity was the strongest prognostic factor. A total of 22 patients electively stopped therapy in BM MRD-negative remission after a median of 8 cycles, with 2-year treatment-free remission of 88%. In patients with NPM1-mutated AML attaining remission with venetoclax combination therapies, NPM1 MRD provides valuable prognostic information.
Publisher
American Society of Hematology
Keywords
Humans; Prognosis; *Nucleophosmin; Mutation; *Leukemia, Myeloid, Acute/drug therapy/genetics; Cytarabine; Neoplasm, Residual/genetics; *Sulfonamides; *Bridged Bicyclo Compounds, Heterocyclic
Department(s)
Pathology; Clinical Haematology
Open Access at Publisher's Site
https://doi.org/10.1182/blood.2023021579
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-03-13 05:27:12
Last Modified: 2024-03-13 05:27:28

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙